Drug Profile
Hydrocodone extended release - Assertio Therapeutics
Alternative Names: Abuse-deterrent extended-release hydrocodone - Assertio Therapeutics; AD ER hydrocodone - Assertio Therapeutics; Egalet-004; S 718632Latest Information Update: 08 Jan 2022
Price :
$50
*
At a glance
- Originator Egalet
- Developer Zyla Life Sciences
- Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 20 May 2020 Assertio Therapeutics has been merged with Zyla Life Sciences to form Assertio Therapeutics
- 03 Jun 2019 Hydrocodone extended release - Egalet is available for licensing as of 31 Dec 2018
- 31 Dec 2018 Discontinued - Phase-I for Pain in USA (PO), as the company is exploring possibilities for further development